Medicare Enrolled
Dr. Riad Dali Ahmad, MD
Infectious Disease · Grand Blanc, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Dali Ahmad from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dali Ahmad?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Dali Ahmad
Dr. Riad Dali Ahmad is an infectious disease specialist in Grand Blanc, MI, with 19 years of NPI registration. Based on federal Medicare data, Dr. Dali Ahmad performed 732,650 Medicare services across 1,400 unique beneficiaries.
Between the years covered by Open Payments, Dr. Dali Ahmad received a total of $8,385 from 57 pharmaceutical and/or device companies across 552 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in infectious disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Dali Ahmad is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 1% volume in MI
$8,385 industry payments
Medicare Practice Summary
Medicare Utilization ↗732,650
Medicare services
Top 1% in MI for infectious disease
1,400
Unique beneficiaries
$1
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~38,561 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Daptomycin antibiotic injection | 684,757 | $0 | $1 |
| Vedolizumab infusion (Entyvio) This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams. |
23,700 | $17 | $25 |
| Denosumab injection (Prolia/Xgeva) | 9,061 | $18 | $25 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
5,740 | $26 | $110 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
2,550 | $0 | $5 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
1,940 | $47 | $135 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,323 | $60 | $110 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
902 | $21 | $60 |
| Ertapenem sodium injection, 500 mg An injection of ertapenem sodium, an antibiotic medication, administered at a dose of 500 mg. |
712 | $11 | $100 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
428 | $93 | $150 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
371 | $15 | $40 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
288 | $10 | $35 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
179 | $96 | $200 |
| Skin and tissue removal, 20 sq cm or less This procedure involves the surgical excision of skin and underlying tissue from an area measuring 20 square centimeters or smaller. |
130 | $43 | $175 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
116 | $95 | $265 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
114 | $21 | $55 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
100 | $6 | $40 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
74 | $134 | $290 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
69 | $92 | $155 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
37 | $120 | $235 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
31 | $64 | $115 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
28 | $131 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.5% high complexity
95.2% medium
0.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,385
Total received (2018-2024)
Avg $1,198/year across 7 years
Top 7% in MI for infectious disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
57
Companies
552
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,978 (95.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$407 (4.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,517
2023
$1,318
2022
$1,305
2021
$1,016
2020
$867
2019
$1,358
2018
$1,004
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Melinta Therapeutics, LLC
$193
AIMMUNE THERAPEUTICS, INC.
$180
Paratek Pharmaceuticals, Inc.
$145
Insmed, Inc.
$106
ViiV Healthcare Company
$94
Merck Sharp & Dohme LLC
$91
Amgen Inc.
$86
Smith+Nephew, Inc.
$82
Octapharma USA, Inc.
$75
Lilly USA, LLC
$62
ABBVIE INC.
$54
Ferring Pharmaceuticals Inc.
$48
Organogenesis Inc.
$40
Solventum Corporation
$33
CashFlow Solutions, LLC
$31
Eisai Inc.
$23
Tactile Systems Technology Inc
$23
Boston Scientific Corporation
$22
MIMEDX Group, Inc.
$21
Genentech USA, Inc.
$21
Novartis Pharmaceuticals Corporation
$19
Integra LifeSciences Corporation
$19
Gilead Sciences, Inc.
$18
PFIZER INC.
$17
La Jolla Pharmaceutical Company
$14
Top 3 companies account for 34.2% of 2024 payments
All-time payments by company (2018-2024) ›
ViiV Healthcare Company
$1,188
Melinta Therapeutics, LLC
$773
Paratek Pharmaceuticals, Inc.
$447
Horizon Therapeutics plc
$427
Organogenesis Inc.
$397
Gilead Sciences, Inc.
$394
Merck Sharp & Dohme Corporation
$353
Insmed, Inc.
$324
Astellas Pharma US Inc
$300
AIMMUNE THERAPEUTICS, INC.
$289
Smith+Nephew, Inc.
$283
Amgen Inc.
$280
Merck Sharp & Dohme LLC
$243
Takeda Pharmaceuticals U.S.A., Inc.
$225
La Jolla Pharmaceutical Company
$197
Ferring Pharmaceuticals Inc.
$191
Melinta Therapeutics, Inc.
$185
Shionogi Inc
$184
Urgo Medical North America, LLC
$129
Smith & Nephew, Inc.
$122
PFIZER INC.
$103
ABBVIE INC.
$98
Theravance Biopharma, Inc.
$88
AbbVie Inc.
$79
TETRAPHASE PHARMACEUTICALS, INC.
$76
Octapharma USA, Inc.
$75
E.R. Squibb & Sons, L.L.C.
$71
ORGANOGENESIS INC.
$70
Lilly USA, LLC
$62
Janssen Biotech, Inc.
$48
Integra LifeSciences Corporation
$42
RGH Enterprises, Inc.
$42
Cumberland Pharmaceuticals, Inc.
$37
Genentech USA, Inc.
$33
Solventum Corporation
$33
AMAG Pharmaceuticals, Inc.
$33
CashFlow Solutions, LLC
$31
MAYNE PHARMA INC.
$31
Organon LLC
$29
Horizon Pharma plc
$29
Allergan Inc.
$29
GlaxoSmithKline, LLC.
$27
AstraZeneca Pharmaceuticals LP
$25
Eisai Inc.
$23
Tactile Systems Technology Inc
$23
Avanir Pharmaceuticals, Inc.
$22
AngioDynamics, Inc.
$22
Boston Scientific Corporation
$22
MIMEDX Group, Inc.
$21
Daiichi Sankyo Inc.
$20
ARGENX US, INC.
$20
Novartis Pharmaceuticals Corporation
$19
HARTMANN USA, INC.
$17
KCI USA, Inc
$16
Aroa Biosurgery Incorporated
$15
ConvaTec Inc.
$12
Allergan, Inc.
$11
Top 3 companies account for 28.7% of all-time payments
Associated products mentioned in payments ›
ACTIV.A.C. · AFFINITY · AQUACEL AG · AVSOLA · AVYCAZ · Affinity · Allevyn Life · Apligraf · Arikayce · Baxdela · CABENUVA · CAPVAXIVE · COLLAGENASE SANTYL · DALVANCE · DELSTRIGO · DIFICID · DOVATO · ENTYVIO · EVENITY · Entyvio · FASENRA · FERAHEME · Fetroja · Flexitouch Plus · GATTEX · GRAFIX PL · INFLECTRA · INJECTAFER · ISENTRESS · JULUCA · KRYSTEXXA · Kimyrsa · LEQVIO · LYMPHA PRESS OPTIMAL PLUS(US) BT · Leqembi · MYCAMINE · NUCALA · NUZYRA · NuShield · Nuedexta · OASIS · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OMNIGRAFT · OMVOH · ORENCIA · Orbactiv · PANZYGA · PICO · PICO 7 · PIFELTRO · PREVNAR 20 · PURAPLY AM · PuraPly AM · Puraply · Puraply Antimicrobial · RAYOS · REBYOTA · RENFLEXIS · Rezzayo · SNAP · STRAVIX · Santyl · Symtuza · TCC-EZ · TEFLARO · TEPEZZA · UPLIZNA · VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP · VIBATIV · VOWST · VYVGART · Vabomere · Varithena Administration Pack · Vibativ · XERAVA · Xerava · Xolair · ZERBAXA · Zetuvit Plus
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 7% for infectious disease in MI.
Geographic Context
Infectious diseases within 10 mi
7
Per 100K population
1.7
County median income
$60,673
Nearest hospital
ASCENSION GENESYS HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Dali Ahmad is a mixed practice specialist, with above-average Medicare volume (top 1% in MI), with low-engagement industry engagement in the top 7% of MI peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Dali Ahmad experienced with daptomycin antibiotic injection?
Based on Medicare claims data, Dr. Dali Ahmad performed 684,757 daptomycin antibiotic injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Dali Ahmad receive payments from pharmaceutical companies?
Yes. Dr. Dali Ahmad received a total of $8,385 from 57 companies across 552 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dali Ahmad's costs compare to other infectious diseases in Grand Blanc?
Dr. Dali Ahmad's average Medicare payment per service is $1. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dali Ahmad) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Infectious Diseases in Grand Blanc
Browse infectious diseases in Grand Blanc ranked by procedure volume and transparency data.
Highest volume
Top Infectious Diseases in MI
Infectious diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Infectious Diseases in MI
Which MI infectious diseases receive the most from drug and device companies.
By company
ViiV Healthcare Company Payments to Doctors
See all physicians who received payments from ViiV Healthcare Company.
By company
Melinta Therapeutics, LLC Payments to Doctors
See all physicians who received payments from Melinta Therapeutics, LLC.
By company
Paratek Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Paratek Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology